We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




X-ray Study Explains How Takinib Inhibits TNF-alpha

By LabMedica International staff writers
Posted on 29 Aug 2017
Takinib, a selective TAK1 inhibiting drug, has been shown to broaden the therapeutic efficacy of TNF-alpha (Tumor necrosis factor-alpha) inhibition for treating cancer and autoimmune diseases.

TAK1 (also known as MAP3K7 or mitogen-activated protein kinase kinase kinase 7) is a key mediator between survival and cell death in TNF-alpha-mediated signaling. More...
TNF-alpha is a cytokine that has a wide variety of functions. It can cause cytolysis of certain tumor cell lines and is a potent pyrogen, causing fever by direct action or by stimulation of interleukin-1 secretion. It can stimulate cell proliferation and induce cell differentiation under certain conditions.

Investigators at Duke University (Durham, NC, USA) recently described the compound Takinib, a potent and selective TAK1 inhibitor that induced apoptosis following TNF-alpha stimulation in cell models of rheumatoid arthritis and metastatic breast cancer.

The investigators used X-ray crystallography to demonstrate that Takinib was an inhibitor of autophosphorylated and non-phosphorylated TAK1 that bound within the ATP-binding pocket and inhibited TAK1 by slowing down the rate-limiting step of TAK1 activation.

Overall, the investigators saw Takinib as an attractive starting point for the development of inhibitors that sensitize cells to TNF-alpha-induced cell death, with general implications for cancer and autoimmune disease treatment.

"The delicate balance between survival and death is often disrupted in disease, and this molecule is able to target the process," said senior author Dr. Timothy Haystead, professor of pharmacology and cancer biology at Duke University. "This compound could potentially enhance the positive parts of TNF-alpha by only targeting tumor cells or inflammatory cells."

The study was published in the August 17, 2017, issue of the journal Cell Chemical Biology.

Related Links:
Duke University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.